Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE.
Publication|Articles|March 30, 2026
- ONCOLOGY Vol 40, Issue 2
- Volume 40
- Issue 02
- Pages: 74-79
Lifesaving Upgrades: Reviewing 40 Years of FDA Oncology Approvals
Author(s)Tim Cortese
ONCOLOGY has identified FDA approvals that have affected the oncology treatment paradigm over the last 40 years.
Advertisement
Advertisement
Over the past 40 years, hundreds of drugs have been approved across a multitude of cancer types. With numbers so great, it is guaranteed that some will fall to the wayside and be forgotten while others will persist throughout decades, affecting treatment paradigms even 30 years down the line. In celebration of the journal ONCOLOGY’s 40th anniversary, it was only fitting to document prominent FDA oncology approvals, starting from 1986 and ending in 2026.
Related to this article
The panel discussed the risk-benefit profile of the Galleri multicancer early detection test, which was evaluated in the NHS-Galleri and PATHFINDER 2 studies.
Data from the phase 3 MK-3475A-D77 trial support the Japanese approval of subcutaneous pembrolizumab and berahyaluronidase alfa.
The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.
Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.
In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.
Advertisement
Advertisement